VERA_Thumbnail.jpg
Vera Therapeutics Scheduled to Present at September Investor Conferences
August 31, 2023 08:00 ET | Vera Therapeutics
BRISBANE, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
VERA_Thumbnail.jpg
Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results
August 10, 2023 08:00 ET | Vera Therapeutics
Presented positive 36-week results from the Phase 2b ORIGIN clinical trial of atacicept in IgAN as a late breaking clinical trial at the 60th ERA CongressInitiated Phase 3 ORIGIN 3 clinical trial of...
Figure 1
Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress
June 17, 2023 10:10 ET | Vera Therapeutics
New data at week 36 shows atacicept 150 mg resulted in a delta of 43% versus placebo in mean proteinuria reduction in per-protocol analysis and demonstrated statistically significant stabilization of...
VERA_Thumbnail.jpg
Vera Therapeutics to Host Presentation of Week 36 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN
June 15, 2023 16:44 ET | Vera Therapeutics
BRISBANE, Calif., June 15, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for...
VERA_Thumbnail.jpg
Vera Therapeutics to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
June 08, 2023 08:00 ET | Vera Therapeutics
BRISBANE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
VERA_Thumbnail.jpg
Vera Therapeutics Initiates Pivotal Phase 3 (ORIGIN 3) Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (IgAN)
June 07, 2023 08:00 ET | Vera Therapeutics
Pivotal Phase 3 Trial for Atacicept in IgA Nephropathy Initiated Today Late-breaking results of ORIGIN Phase 2b trial supporting further evaluation of atacicept 150 mg as a potential...
VERA_Thumbnail.jpg
Vera Therapeutics Provides Business Update and Reports First Quarter Financial Results
May 11, 2023 07:30 ET | Vera Therapeutics
36-week data from the Phase 2b ORIGIN clinical trial of atacicept in IgAN selected for presentation as a late breaking clinical trial at ERA Congress 2023 Plan to initiate a pivotal Phase 3 clinical...
VERA_Thumbnail.jpg
Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs
May 04, 2023 08:00 ET | Vera Therapeutics
BRISBANE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for...
VERA_Thumbnail.jpg
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
March 28, 2023 07:30 ET | Vera Therapeutics
Announced positive interim data from the Phase 2b ORIGIN clinical trial of atacicept in IgAN, which showed a 41% mean reduction in proteinuria versus baseline in the 150mg dose group at 24...
VERA_Thumbnail.jpg
Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
February 27, 2023 16:05 ET | Vera Therapeutics
BRISBANE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for...